Similarly, the combination of momelotinib and sorafenib efficiently suppressed the tumor-initiating ability in xenograft models (Figure 7) and effectively inhibited the expression of Ki-67, a marker for representing tumor proliferation. The gene discussed is MKI67; the disease is neoplasm.